CClinicalTrials.gg
Status unknownNCT04622748Updated Nov 10, 2020

Neurocognitive Functions of Recovered COVID-19 Patients

An observational study in Cognition and Covid-19, sponsored by National Institute on Drug Dependence, China. Status unknown at 1 site in China. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2020-11-10.

Sponsored by National Institute on Drug Dependence, China · Observational

The sponsor has not verified this record recently (last verified Sep 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
160
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study is carried on in Wuchang Hospital in Wuhan, China. The investigators plan to recruit 80 patients with COVID-19 and 80 matched healthy control. Using the design of case-control study, the study aims to assess the neurocognitive functions such as executive function and attentional bias in recovered patients with COVID-19 under normal and stress conditions, and to analyze the influencing factors of neurocognitive functions, such as mental health conditions, inflammation indicators and cardiopulmonary function.

02

Conditions studied

  • Cognition
  • Covid-19

Browse trials for

03

In context

COVID-19

7,640 studies on the registry are indexed under COVID-19; 488 are open to participants now.

This study's planned enrollment of 160 is below the median of 261 across 3,136 observational studies indexed under COVID-19.

Browse COVID-19 studies →

Lead sponsor

National Institute on Drug Dependence, China is the lead sponsor of 7 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Recovered COVID-19 patients and uninfected residents in Wuhan

Inclusion criteria

  • Recovered COVID-19 patients or uninfected residents in Wuhan, with an education level above elementary school and are able to complete cognitive tasks;
  • Willing to participate in this study and sign informed consent.

Exclusion criteria

Exclusion Criteria:

  • Subjects with body temperature> 38°C;
  • Subjects who are in menstruation and pregnancy;
  • Subjects suffering from cardiopulmonary diseases before the new coronary pneumonia epidemic (such as heart disease, pulmonary hypertension, congestive heart failure, etc.);
  • Subjects with severe disturbances in consciousness, cognitive dysfunction, mental disorders, visual and hearing disorders, bone and joint diseases, etc.;
  • Subjects with abnormal immune system and severe organ dysfunction (heart, liver, kidney, etc.);
  • Subjects who are unwilling to participate in this study and cannot complete all surveys and cognitive function tests.
05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
160 participants (estimated)
Patient registry
No

Groups and cohorts

  • COVID-19

    Recovered COVID-19 patients in Wuhan

    Behavioral: Trier Social Stress Test

  • Healthy Control

    Uninfected people in Wuhan

    Behavioral: Trier Social Stress Test

Interventions

  • BehavioralTrier Social Stress Test

    8-min oral calculation and 5-min speech

06

What researchers measure

Primary outcomes

  1. working memory

    assessed by the n-back task, including 0-back, 1-back and 2-back

    Time frame: 10 minutes

  2. Cognitive flexibility

    assessed by the trail-making task

    Time frame: 3 minutes

  3. Inhibitory control

    assessed by the stroop task

    Time frame: 10 minutes

Secondary outcomes

  1. Attention Bias

    assessed by the dot-probe task

    Time frame: 15 minutes

  2. Serum TNFalpha

    Concentration of serum TNFalpha in ng/ml will be assessed by ELISA

    Time frame: 1 day

  3. Serum IL-6

    Concentration of serum IL-6 in ng/ml will be assessed by ELISA.

    Time frame: 1 day

  4. CRP

    hypersensitive C-reactive protein(hs-CRP) in mg/L will be assessed by Turbidimetric inhibition immuno assay.

    Time frame: 1 day

  5. Depression

    assessed by Self-Rating Depression Scale, which is consist of 20 items scoring 1 to 4.

    Time frame: 3-5 minutes

  6. Anxiety

    assessed by Self-Rating Anxiety Scale, which is consist of 20 items scoring 1 to 4.

    Time frame: 3-5 minutes

  7. PTSD

    assessed by PTSD Checklist for DSM-5 (PCL-5)

    Time frame: 3-5 minutes

  8. Sleep

    assessed by Pittsburgh sleep quality index (PSQI)

    Time frame: 3-5 minutes

  9. General cognition

    assessed by Montreal - Cognitive Assessment (MoCA)

    Time frame: 8-10 minutes

  10. Cardiopulmonary function 1

    maximal inspiration pressure(MIP), maximal expiration pressure(MEP)

    Time frame: 15 minutes

  11. Cardiopulmonary function 2

    Assessed by the 6-minutes' walk test

    Time frame: 10 minutes

Other outcomes

  1. Stress response indicator 1

    concentration of saliva cortisol stress, assessed by ELISA

    Time frame: Saliva samples will be colleted before stress, 0 minutes and 10 minutes after stress.

  2. Stress response indicator 2

    Hear rates

    Time frame: Assessed before and 0 minute after stress

  3. Stress response indicator 3

    Blood pressure before stress and after stress

    Time frame: Assessed before and 0 minute after stress

07

Study locations

1 of 1 sites recruiting
  • Wuhan Wuchang Hospital
    Wuhan, Hubei 430063, China
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 10, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04622748
Lead sponsor
National Institute on Drug Dependence, China
Collaborators
Peking University Sixth Hospital, Wuhan Wuchang Hospital
Responsible party
Sponsor
First posted
Nov 10, 2020
Start date
Jul 10, 2020
Primary completion
Dec 10, 2020 (estimated)
Completion
Dec 10, 2020 (estimated)
Last update
Nov 10, 2020

Study contacts

Ping Wu, Dr.
Contact
wuping@bjmu.edu.cn
861082802470 ext. 509
Lin Lu, Dr.
study director · National Institute on Drug Dependence, Peking University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Sep 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion